Fischgrabe J, Wulfing P: Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 2009, 3: 85. 10.2174/157488408784293732
Article
Google Scholar
Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM: The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int JCancer 1991, 49: 323. 10.1002/ijc.2910490302
Article
CAS
Google Scholar
Naran S, Zhang X, Hughes SJ: Inhibiton of HGF/Met as therapy for malignancy. Expert Opin Ther Targets 2009, 13: 569. 10.1517/14728220902853917
Article
CAS
PubMed
Google Scholar
Gentile A, Trusolino L, Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008, 27: 85. 10.1007/s10555-007-9107-6
Article
CAS
PubMed
Google Scholar
Gastaldi S, Comoglio PM, Trusolino L: The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res 2010, 12: 208. 10.1186/bcr2617
Article
PubMed Central
PubMed
Google Scholar
Geho DH, Bandle RW, Clair T, Liotta LA: Physiological mechanisms of tumor-cell invasion and migration. Physiology (Bethesda) 2005, 20: 194. 10.1152/physiol.00009.2005
Article
CAS
Google Scholar
Porter AC, Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998, 17: 1343. 10.1038/sj.onc.1202171
Article
CAS
PubMed
Google Scholar
Elliott BE, Hung WL, Boag AH, Tuck AB: The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can J Physiol Pharmacol. 2002, 80: 91. 10.1139/y02-010
Article
CAS
PubMed
Google Scholar
Sattler M, Salgia R: c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007, 9: 102. 10.1007/s11912-007-0005-4
Article
CAS
PubMed
Google Scholar
Eder JP, Vande Woude GF, Boerner SA, LoRusso PM: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15: 2207. 10.1158/1078-0432.CCR-08-1306
Article
CAS
PubMed
Google Scholar
Cooke VG, LeBleu VS, Keskin D, Khan Z, O'Connell JT, Teng Y, Duncan MB, Xie L, Maeda G, Vong S, Sugimoto H, Rocha RM, Damascena A, Brentani RR, Kalluri R: Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21: 66. 10.1016/j.ccr.2011.11.024
Article
PubMed Central
CAS
PubMed
Google Scholar
Tomaskovic-Crook E, Thompson EW, Thiery JP: Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11: 213. 10.1186/bcr2416
Article
PubMed Central
PubMed
Google Scholar
Ma PC, Maulik G, Christensen J, Salgia R: c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003, 22: 309. 10.1023/A:1023768811842
Article
CAS
PubMed
Google Scholar
Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K: Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011, 10: 169. 10.1158/1535-7163.MCT-10-0544
Article
CAS
PubMed
Google Scholar
Reshetnikova G, Troyanovsky S, Rimm DL: Definition of a direct extracellular interaction between met and E-cadherin. Cell Biol Int 2007, 31: 366. 10.1016/j.cellbi.2007.01.022
Article
CAS
PubMed
Google Scholar
Micalizzi DS, Farabaugh SM, Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010, 15: 117. 10.1007/s10911-010-9178-9
Article
PubMed Central
PubMed
Google Scholar
Takebe N, Warren RQ, Ivy SP: Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 2011, 13: 211. 10.1186/bcr2876
Article
PubMed Central
PubMed
Google Scholar
Hu J, Shao S, Song Y, Zhao J, Dong Y, Gong L, Yang P: Hepatocyte growth factor induces invasion and migration of ovarian cancer cells by decreasing the expression of E-cadherin, beta-catenin, and caveolin-1. Anat Rec (Hoboken) 2010, 293: 1134. 10.1002/ar.21147
Article
CAS
Google Scholar
Singh A, Settleman J: EMT, cancer stem cells and drug reistance: and emerging axis of evil in the war on cancer. Oncogene 2010, 29: 4741. 10.1038/onc.2010.215
Article
PubMed Central
CAS
PubMed
Google Scholar
Ke Q, Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70: 1469. 10.1124/mol.106.027029
Article
CAS
PubMed
Google Scholar
Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92: 5510. 10.1073/pnas.92.12.5510
Article
PubMed Central
CAS
PubMed
Google Scholar
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the Met protooncogene. Cancer Cell 2003, 3: 347. 10.1016/S1535-6108(03)00085-0
Article
PubMed
Google Scholar
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992, 119: 629. 10.1083/jcb.119.3.629
Article
CAS
PubMed
Google Scholar
Ayoub NM, Bachawal SV, Sylvester PW: γ-Tocotrienol inhibits Met expression and activation in highly malignant mammary tumor cells. Cell Proliferation 2011, 44: 516. 10.1111/j.1365-2184.2011.00785.x
Article
CAS
PubMed
Google Scholar
Ayoub NM, Akl MR, Sylvester PW: Combined γ-tocotrienol and Met inhibitor treatment suppresses cancer cell proliferation, epithelial-to-mesenchymal transition, and migration. Cell Proliferation 2013, 46: 538.
CAS
PubMed
Google Scholar
Toschi L, Janne PA: Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/Met signaling in cancer. Clin Cancer Res 2008, 14: 5941. 10.1158/1078-0432.CCR-08-0071
Article
CAS
PubMed
Google Scholar
Knudsen BS, Vande Woude G: Showering c-Met-dependent cancers with drugs. Curr Opin Genet Dev 2008, 19: 87. 10.1016/j.gde.2008.02.001
Article
Google Scholar
Stellrecht CM, Gandhi V: Met receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009, 280: 1. 10.1016/j.canlet.2008.10.045
Article
CAS
PubMed
Google Scholar
Liu X, Yao W, Newton RC, Scherle PA: Targeting the c-Met signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008, 17: 997. 10.1517/13543784.17.7.997
Article
CAS
PubMed
Google Scholar
Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF: Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009, 106: 12909. 10.1073/pnas.0810403106
Article
PubMed Central
CAS
PubMed
Google Scholar
Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF: A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19: 4947. 10.1038/sj.onc.1203874
Article
CAS
PubMed
Google Scholar
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kin TS, Tasker A, Burgess TL, Dussault I: c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008, 283: 2675. 10.1074/jbc.M705774200
Article
CAS
PubMed
Google Scholar
Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF: Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009, 100: 941. 10.1038/sj.bjc.6604937
Article
PubMed Central
CAS
PubMed
Google Scholar
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005, 65: 1479. 10.1158/0008-5472.CAN-04-2650
Article
CAS
PubMed
Google Scholar
Sattler M, Salgia R: The MET axis as a therapeutic target. Update Cancer Ther 2009, 3: 109. 10.1016/j.uct.2009.01.001
Article
PubMed Central
PubMed
Google Scholar
Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia RA: A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003, 9: 102.
Google Scholar
Lawrence RE, Salgia R: MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr 2010, 4: 146. 10.4161/cam.4.1.10973
Article
PubMed Central
PubMed
Google Scholar
Smyth EC, Sclafani E, Cunningham D: Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014. doi:10.2147/OTT.S44941. Smyth EC, Sclafani E, Cunningham D: Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Onco Targets Ther 2014. doi:10.2147/OTT.S44941.
Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Dern JA, Ma PC: Dual MET-EGFR combinational inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008, 99: 911. 10.1038/sj.bjc.6604559
Article
PubMed Central
CAS
PubMed
Google Scholar
Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D: Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009, 20: 2495. 10.1091/mbc.E08-09-0969
Article
PubMed Central
CAS
PubMed
Google Scholar
Sierra JR, Tsao MS: c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol 2011, 3: S21. 10.1177/1758834011422557
Article
PubMed Central
CAS
PubMed
Google Scholar
Kass L, Erler JT, Dembo M, Weaver VM: Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007, 39: 1987. 10.1016/j.biocel.2007.06.025
Article
PubMed Central
CAS
PubMed
Google Scholar
Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M: Met induces mammary tumors with diverse histologies and is associated with poor outcome and human breast cancer. Proc Natl Acad Sci USA 2009, 106: 12903. 10.1073/pnas.0810402106
Article
PubMed Central
CAS
PubMed
Google Scholar
Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS, Park JH: Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem 2012, 359: 431. 10.1007/s11010-011-1039-3
Article
CAS
PubMed
Google Scholar
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KEE, Zimmer Y: The Met kinase inhibitor SU11274 exhibits a selective inhibition patter toward different receptor mutated variants. Oncogene 2004, 23: 5387. 10.1038/sj.onc.1207691
Article
CAS
PubMed
Google Scholar
Tanizaki J, Okamoto I, Sakai K, Nakagawa K: Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 2011, 105: 807. 10.1038/bjc.2011.322
Article
PubMed Central
CAS
PubMed
Google Scholar
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T: Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998, 17: 3045. 10.1038/sj.onc.1202231
Article
CAS
PubMed
Google Scholar
Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 2001, 98: 7443. 10.1073/pnas.131200498
Article
PubMed Central
CAS
PubMed
Google Scholar
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P: An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004, 114: 1418. 10.1172/JCI22235
Article
PubMed Central
CAS
PubMed
Google Scholar
Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c- Met-dependent human tumors. Cancer Res 2006, 66: 1721. 10.1158/0008-5472.CAN-05-3329
Article
CAS
PubMed
Google Scholar
Sylvester PW, Theriault A: Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res 2003, 1: 121.
CAS
Google Scholar
Sylvester PW: Antiproliferative and apoptotic effects of tocotrienols on normal and neoplastic mammary epithelial cells. In tocotrienols: vitamin E beyond tocopherols. Edited by: Watson RR, Preedy VR. CRC Press, Boca Raton; 2008:119. 10.1201/9781420080391.ch10
Chapter
Google Scholar
McIntyre BS, Briski KP, Tirmenstein M, Fariss MW, Gapor A, Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols in normal mouse mammary epithelial cell. Lipids 2000, 35: 171. 10.1007/BF02664767
Article
CAS
PubMed
Google Scholar
McIntyre BS, Briski KP, Gapor A, Sylvester PW: Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 2000, 224: 292. 10.1046/j.1525-1373.2000.22434.x
Article
CAS
PubMed
Google Scholar
Samant GV, Sylvester PW: gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 2006, 39: 563. 10.1111/j.1365-2184.2006.00412.x
Article
CAS
PubMed
Google Scholar
Bachawal SV, Wali VB, Sylvester PW: Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 2010, 30: 429.
CAS
PubMed
Google Scholar
Bachawal SV, Wali VB, Sylvester PW: Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 2010, 10: 84. 10.1186/1471-2407-10-84
Article
PubMed Central
PubMed
Google Scholar
Holmgren L: Antiangiogenesis restricted tumor dormancy. Cancer Metastasis Rev 1996, 15: 241. 10.1007/BF00437478
Article
CAS
PubMed
Google Scholar
Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15: 551. 10.1146/annurev.cellbio.15.1.551
Article
CAS
PubMed
Google Scholar
Semenza GL: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000, 19: 59. 10.1023/A:1026544214667
Article
CAS
PubMed
Google Scholar
Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8: S62. 10.1016/S1471-4914(02)02317-1
Article
CAS
PubMed
Google Scholar
Josko J, Gwozdz B, Jedrzejowska-Szypulka H, Hendryk S: Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000, 6: 1047.
CAS
PubMed
Google Scholar
Ananthula S, Parajuli P, Behery FA, El Sayed KA, Sylvester PW: γ-Tocotrienol oxazine derivative antagonizes mammary tumor cell compensatory responses to CoCl2-induced hypoxia.Biomed Res Int 2014. .[http://dx.doi.org/10.1155/2014/285752].